PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast - April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

09/30/21 • 58 min

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.

Previous Episode

undefined - Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients

Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients

Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.

Next Episode

undefined - Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care

Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care

Go online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Appraise recent efficacy and safety data on newly available, guideline-based, and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Summarize ongoing/accruing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, for patients with advanced biliary cancers, Apply practice-changing clinical trial evidence to personalize the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics.